Stem Cell Reports
Volume 5, Issue 3, 8 September 2015, Pages 392-404
Journal home page for Stem Cell Reports

Article
Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses

https://doi.org/10.1016/j.stemcr.2015.07.013Get rights and content
Under a Creative Commons license
open access

Highlights

  • hMSC-secreted IL-25 suppress Th17 responses in vitro and in vivo

  • IL-25 alone is insufficient to significantly suppress Th17 responses

  • IL-25 upregulates PD-L1 expression in hMSCs to suppress Th17 cells

  • IL-25-mediated PD-L1 expression can be driven by STAT3

Summary

Multipotent human mesenchymal stromal cells (hMSCs) harbor immunomodulatory properties that are therapeutically relevant. One of the most clinically important populations of leukocytes is the interleukin-17A (IL-17A)-secreting T (Th17) lymphocytes. However, mechanisms of hMSC and Th17 cell interactions are incompletely resolved. We found that, along with Th1 responses, hMSCs strongly suppressed Th17 responses and this required both IL-25—also known as IL-17E—as well as programmed death ligand-1 (PD-L1), a potent cell surface ligand for tolerance induction. Knockdown of IL-25 expression in hMSCs abrogated Th17 suppression in vitro and in vivo. However, IL-25 alone was insufficient to significantly suppress Th17 responses, which also required surface PD-L1 expression. Critically, IL-25 upregulated PD-L1 surface expression through the signaling pathways of JNK and STAT3, with STAT3 found to constitutively occupy the proximal region of the PD-L1 promoter. Our findings demonstrate the complexities of hMSC-mediated Th17 suppression, and highlight the IL-25/STAT3/PD-L1 axis as a candidate therapeutic target.

Cited by (0)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

8

Co-first author